Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
C

Protocol

B vitamins (folic acid, B6, B12) for brain shrinkage in mild cognitive impairment

In VITACOG, 168 older adults with mild cognitive impairment who took high-dose folic acid, vitamin B6 and vitamin B12 for two years lost brain volume more slowly on MRI (0.76% a year against 1.08%), most clearly in those with high homocysteine An amino acid in the blood that rises when vitamin B12, folate or B6 are low..

Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →

Compare this record with another, side by side →

At a glance

In plain words

Older adults with mild memory problems took high doses of B vitamins or a dummy pill for two years. On brain scans, the vitamin group lost brain volume more slowly. The effect was largest in people with high homocysteine, a blood marker the vitamins lower. Scans are not the same as memory, and the trial did not show less dementia.

The letter, taken apart
What was measured
Brain volume loss on MRI over 2 years.
How big
Brain atrophy was 0.76% a year against 1.08% a year with placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received..Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 20838622.
Who it applies to
Older adults with mild cognitive impairment.
Safety
Serious side effects were no more common than with placebo.
The record in one view
Compared with
Placebo.
Certainty
Grade C, resting on: One randomized trial with an imaging outcome.
What would change this grade
Could rise to B with: Randomized trial of B vitamins. Who: Older adults with mild cognitive impairment and high homocysteine. Measured: Conversion to dementia. Length: At least 3 years.
Cost
No price recorded yet.
Sources
1 study cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
CSurrogate biomarker Grade C

In VITACOG, 168 older adults with mild cognitive impairment who took high-dose folic acid, vitamin B6 and vitamin B12 for two years lost brain volume more slowly on MRI (0.76% a year against 1.08%), most clearly in those with high homocysteine. Brain volume is an imaging measure, not a clinical outcome.

Why this letter

Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Why this grade

Grade C on brain atrophy. One trial found B vitamins slowed brain shrinkage on MRI in mild cognitive impairment (Smith et al., 2010; PMID 20838622).

WHY NOT Bbrain volume on MRI is not an established stand-in for dementia or cognitive decline, and the result has not been replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. in a trial of dementia.

WHAT THIS GRADE DOES NOT COVERpeople without high homocysteine or without cognitive impairment, and dementia itself. It also does not cover memory and thinking scores, which were secondary measures and do not carry this letter.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial

Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Rate of brain atrophy on MRI (surrogate)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of B vitamins
PopulationOlder adults with mild cognitive impairment and high homocysteine
EndpointConversion to dementia
DurationAt least 3 years

A positive trial of this shape, supported by further trials, would move this entry to B.

Why the current trials fall short

A trial measuring dementia would be needed.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Vitamin B Complex among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Vitamin B Complex on ClinicalTrials.gov

Dose, form and timing

What to track

Homocysteine.

Safety

Safety evidence, by strength

No safety data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 470 · November 2026 · First graded.
Grade history
No. 470 · November 2026 · First graded
B vitamins (folic acid, B6, B12) for brain shrinkage in mild cognitive impairment is added from the gap report: Grade C

New record in the gap-report batch. In VITACOG, 168 older adults with mild cognitive impairment who took high-dose folic acid, vitamin B6 and vitamin B12 for two years lost brain volume more slowly on MRI (0.76% a year against 1.08%), most clearly in those with high homocysteine. Brain volume is an imaging measure, not a clinical outcome.PMID 20838622

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullOne paper, linked to its PubMed record.
The evidence

Smith et al. (PLoS One, 2010; PMID 20838622): VITACOG, randomized placebo-controlled trial, 168 completers with mild cognitive impairment, folic acid 0.8 mg, vitamin B6 20 mg and vitamin B12 0.5 mg daily for 24 months; brain atrophy 0.76% a year against 1.08%; 53% lower atrophy rate with homocysteine above 13 micromol/L; no difference in serious adverse events.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 8 records screened, 1 eligible for the graded claim.
Query: ("B vitamin*"[tiab] OR "folic acid"[tiab]) AND (atrophy[tiab] OR cognitive[tiab]) AND homocysteine[tiab] AND randomized controlled trial[pt]
The 8 most recent of 61 records were screened by title; none is a replication of VITACOG (PMID 20838622) with dementia as the outcome.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Smith et al., 2010, PLoS One (PMID 20838622): PubMed lists funding from Medical Research Council. The PubMed record carries a competing-interest statement.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026